Cargando…

ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL

PURPOSE: High dose methotrexate (HD-MTX) followed by radiotherapy (RT) is a standard therapy for primary CNS malignant lymphoma. However, the delayed neuronal toxicity due to RT is a serious problem especially for elderly patients. To avoid RT toxicity, we performed re-challenge of HD-MTX until comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaguchi, Takashi, Nagayama, Rie, Gomi, Akira, Kawai, Kensuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213239/ http://dx.doi.org/10.1093/noajnl/vdz039.155

Ejemplares similares

ML-14 Re-challenge and maintenance therapy of methotrexate for elderly PCNSL patients with low scored KPS
por: Yamaguchi, Takashi, et al.
Publicado: (2020)

Implementation of an Outpatient HD-MTX Initiative
por: Sokol, Kelsey, et al.
Publicado: (2022)

Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
por: Verkaaik, M, et al.
Publicado: (2011)

Monoclonal antibody targeting of methotrexate (MTX) against MTX-resistant tumour cell lines.
por: Affleck, K., et al.
Publicado: (1992)

Impairment of Methotrexate (MTX)‐Polyglutamate Formation of MTX‐resistant K562 Cell Lines
por: Koizumi, Shoichi
Publicado: (1988)

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL
por: Ohka, Fumiharu, et al.
Publicado: (2021)

Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World
por: Zhang, Le, et al.
Publicado: (2020)

Relationship Between the Free and Total Methotrexate Plasma Concentration in Children and Application to Predict the Toxicity of HD-MTX
por: Dong, Wei-Chong, et al.
Publicado: (2021)

How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy
por: Taylor, Peter. C., et al.
Publicado: (2019)

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
por: Emery, Paul, et al.
Publicado: (2020)

ML-13 The primary treatment outcomes and future problems of PCNSL elderly patients in our institute
por: Kambe, Atsushi, et al.
Publicado: (2020)

Methotrexate (MTX) inhibition of cytokine production: relationship with clinical outcome and genetic polymorphisms
por: Sabina, P, et al.
Publicado: (2003)

GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
por: Vieira-Sousa, Elsa, et al.
Publicado: (2020)

Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia
por: Sari, Nur Melani, et al.
Publicado: (2021)

Complete Genome Sequence of Serratia marcescens Phage MTx
por: Graham, Kristin, et al.
Publicado: (2019)

ML-5 THE TRANSITION OF THE TREATMENT OF 60 PCNSL CASES AT OUR INSTITUTION AND CLINICAL CONSIDERATIONS
por: Yoshitake, Hidenobu, et al.
Publicado: (2022)

ML-4 POLICY CHANGE TO PCNSL TREATMENT LED BY HEMATOLOGY, AND INITIAL TREATMENT RESULTS
por: Hashiba, Tetsuo, et al.
Publicado: (2022)

ML-17 Clinical usefulness of Tirabrutinib in recurrent PCNSL: single institute experience
por: Matsuura, Jin, et al.
Publicado: (2021)

Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy
por: Zhang, Jing, et al.
Publicado: (2020)

Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis
por: Chara, Luis, et al.
Publicado: (2012)

Serious infections in JIA patients upon MTX, TFN inhibitors and combinations
por: Horneff, Gerd, et al.
Publicado: (2014)

Maitotoxin-4, a Novel MTX Analog Produced by Gambierdiscus excentricus
por: Pisapia, Francesco, et al.
Publicado: (2017)

AHR-dependent genes and response to MTX therapy in rheumatoid arthritis patients
por: Wajda, Anna, et al.
Publicado: (2021)

Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis
por: Katchamart, W, et al.
Publicado: (2008)

Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis
por: Donahue, Katrina E., et al.
Publicado: (2019)

Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese
por: Han, Xiao, et al.
Publicado: (2017)

ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)
por: Shinojima, Naoki, et al.
Publicado: (2020)

MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy
por: Shiozawa, Kazuko, et al.
Publicado: (2016)

ML-12 Clinical impact and management of skin-related disorders during treatment of relapsed PCNSL by tirabrutinib
por: Sasaki, Nobuyoshi, et al.
Publicado: (2021)

Mid-board miniature dual channel optical transmitter MTx and transceiver MTRx
por: Zhao, Xiandong, et al.
Publicado: (2020)

Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients
por: Schoemaker, Casper G., et al.
Publicado: (2018)

LETTER TO THE EDITOR Subcutaneous (SC) Methotrexate (MTX) is Better and Well-Tolerable than Oral MTX in Rheumatoid Arthritis Patients, Switched from Oral to SC Administration Due to Gastrointestinal Side Effects
por: Borman, Pinar, et al.
Publicado: (2014)

COVD-23. PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC
por: Schaff, Lauren, et al.
Publicado: (2020)

PB2136: PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC
por: Schaff, L., et al.
Publicado: (2022)

Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies
por: Fukushima, Hiroko, et al.
Publicado: (2013)

Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
por: Saito, Shuntaro, et al.
Publicado: (2019)

Association Between White Blood Cells at Baseline and Treatment Failure of MTX for Ectopic Pregnancy
por: Chen, Si, et al.
Publicado: (2021)

Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis
por: Toyama, Kohtaro, et al.
Publicado: (2023)

PB2347: THE ROLE OF UPFRONT LENALIDOMIDE MAINTENANCE FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS RESPONDING TO FIRST-LINE MTX TREATMENT
por: Zhang, Yan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h8aqrnn7l4nfsnpvlfsqlodjtq